Efficiency of day 4 compared to day 6 stem cell mobilization in allogeneic stem cell donors

被引:1
|
作者
Al-Geithi, Hajer [1 ,3 ]
Al-Mamari, Sahima [2 ,3 ]
Dennison, David [2 ,3 ]
Al-Huneini, Mohamed [2 ,3 ]
Al-Kindi, Salam [2 ,3 ]
Al-Farsi, Khalil [2 ,3 ]
Al-Khabori, Murtadha [2 ,3 ]
机构
[1] Sultan Qaboos Univ, Oman Med Specialty Board, Muscat, Oman
[2] Sultan Qaboos Univ Hosp, Dept Hematol, Muscat, Oman
[3] Sultan Qaboos Univ, Coll Med & Hlth Sci, Muscat, Oman
关键词
Donors; Transplantation; Immunohematology; COLONY-STIMULATING FACTOR; G-CSF; COLLECTION; PLERIXAFOR; COUNTS;
D O I
10.1016/j.transci.2020.102727
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Granulocyte colony stimulating factor (G-CSF) given for 4-6 days is commonly used for mobilization of allogeneic stem cell donors. The primary objective of this study is to compare the yield of stem cell mobilization, assessed using a surrogate endpoint of CD34+ cell count, between Day 4 and Day 6. Study design and Methods: In this retrospective study we included all allogeneic stem cell donors mobilized with G-CSF for 6 days from January 2003 until October 2015 in the bone marrow transplantation unit at a tertiary academic center. Of 106 donor records reviewed, 84 were with available data and selected for the study. Results: We included 84 donors with median age and weight of 19 years and 60 kg respectively. The median Day 4 WBC and CD34(+) cell count were 37.4 x 10(9)/L and 54 x 10(6)/L respectively; while the median Day 6 WBC and CD34(+) cell count were 44.4 x 10(9)/L and 86 x 10(6)/L respectively with a statistically significant difference from Day 4 (P < 0.001). In the multivariable model, there were no significant impact of donor's age (P = 0.215), weight (P = 0.108), height (P = 0.428) and mean corpuscular volume (P = 0.263) on the difference in CD34(+) cell yield. However, the donor's blood group AB predicated a significantly higher difference (P = 0.036). Conclusion: Six days of G-CSF mobilization achieves higher CD34(+) cell count than 4 days in allogeneic stem cell donors especially in donors with blood group AB, albeit both approaches give count higher than the successful collection threshold.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
    Schroeder, Mark A.
    Rettig, Michael P.
    Lopez, Sandra
    Christ, Stephanie
    Fiala, Mark
    Eades, William
    Mir, Fazia A.
    Shao, Jin
    McFarland, Kyle
    Trinkaus, Kathryn
    Shannon, William
    Deych, Elena
    Yu, Jinsheng
    Vij, Ravi
    Stockerl-Goldstein, Keith
    Cashen, Amanda F.
    Uy, Geoffrey L.
    Abboud, Camille N.
    Westervelt, Peter
    DiPersio, John F.
    BLOOD, 2017, 129 (19) : 2680 - 2692
  • [32] Factors affecting hematopoietic stem cell mobilization and apheresis in allogeneic donors: The role of iron status
    Ozkurt, Zubeyde Nur
    Batmaz, Leyla
    Yegin, Zeynep Arzu
    Ilhan, Cigdem
    TRANSFUSION AND APHERESIS SCIENCE, 2017, 56 (03) : 470 - 473
  • [33] Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant
    Al Saleh, Abdullah S.
    Sidiqi, M. Hasib
    Lee, JaeWon
    Dispenzieri, Angela
    Muchtar, Eli
    Buadi, Francis K.
    Warsame, Rahma
    Lacy, Martha Q.
    Dingli, David
    Leung, Nelson
    Gonsalves, Wilson I.
    Kapoor, Prashant
    Kourelis, Taxiarchis V.
    Skaer, Christel A.
    Wittwer, Sarah K.
    Wolf, Robert C.
    Hogan, William J.
    Kumar, Shaji K.
    Jacob, Eapen
    Gertz, Morie A.
    BONE MARROW TRANSPLANTATION, 2020, 55 (11) : 2132 - 2137
  • [34] Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant
    Abdullah S. Al Saleh
    M. Hasib Sidiqi
    JaeWon Lee
    Angela Dispenzieri
    Eli Muchtar
    Francis K. Buadi
    Rahma Warsame
    Martha Q. Lacy
    David Dingli
    Nelson Leung
    Wilson I. Gonsalves
    Prashant Kapoor
    Taxiarchis V. Kourelis
    Christel A. Skaer
    Sarah K. Wittwer
    Robert C. Wolf
    William J. Hogan
    Shaji K. Kumar
    Eapen Jacob
    Morie A. Gertz
    Bone Marrow Transplantation, 2020, 55 : 2132 - 2137
  • [35] Allogeneic blood stem cell transplantation: Considerations for donors
    Anderlini, P
    Korbling, M
    Dale, D
    Gratwohl, A
    Schmitz, N
    Stroncek, D
    Howe, C
    Leitman, S
    Horowitz, M
    Gluckman, E
    Rowley, S
    Przepiorka, D
    Champlin, R
    BLOOD, 1997, 90 (03) : 903 - 908
  • [36] Rhabdomyolysis in allogeneic peripheral blood stem cell donors
    Schanz, J
    Wolf, C
    Koehler, M
    Maas, JH
    Meyer, M
    Neumeyer, H
    Legler, TJ
    Wulf, G
    Glass, B
    Truemper, L
    Riggert, J
    VOX SANGUINIS, 2004, 86 (04) : 263 - 265
  • [37] Use of alternative donors for allogeneic stem cell transplantation
    Anasetti, Claudio
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 220 - 224
  • [38] Allogeneic stem cell transplantations from unrelated donors
    Milpied, N.
    ONCOLOGIE, 2007, 9 (12) : 837 - 841
  • [39] Understanding patient distress on day+100 of allogeneic stem cell transplant.
    Padrnos, Leslie Jane
    Kosiorek, Heidi
    Slack, James L.
    Khera, Nandita
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (03)
  • [40] EFFICACY OF PLERIXAFOR IN CD34+ STEM CELL MOBILIZATION IN HEALTHY PEDIATRIC STEM CELL DONORS
    Bharadwaj, Rishab
    Kumar, Vimal
    Munirathnam, Deenadayalan
    BONE MARROW TRANSPLANTATION, 2024, 59 : 644 - 644